Last updated: February 19, 2026
This report analyzes the patent claims and landscape for Brazil patent BR112016011065, focusing on its technical scope and potential market implications for pharmaceutical stakeholders.
What Does Patent BR112016011065 Claim?
Patent BR112016011065, titled "Method for treating diseases associated with inflammation and autoimmune diseases and pharmaceutical composition," claims a method for treating diseases by administering a specific pharmaceutical composition. The core of the claim lies in the composition, which comprises an immunomodulatory antibody capable of binding to the CD40L molecule and a pharmaceutically acceptable carrier.
The patent explicitly defines the immunomodulatory antibody as one that binds to CD40L. It also specifies that the antibody may be humanized, chimeric, or fully human. The claimed method involves administering a therapeutically effective amount of this composition to a subject in need thereof. The patent further details specific diseases that fall within the scope of its claims, including but not limited to rheumatoid arthritis, lupus, psoriasis, and multiple sclerosis.
The claims extend to the pharmaceutical composition itself, which is defined by its components: the CD40L-binding antibody and the carrier. This dual claim structure—method of treatment and the composition for that treatment—provides broad protection.
What is the Technical Scope of the Patent?
The technical scope of BR112016011065 is centered on the modulation of the CD40 ligand (CD40L) pathway as a therapeutic strategy. CD40L is a transmembrane protein expressed on activated T cells, B cells, and other immune cells. Its interaction with the CD40 receptor on antigen-presenting cells, B cells, and other target cells plays a critical role in immune activation, B cell proliferation, antibody production, and T cell co-stimulation. Dysregulation of this pathway is implicated in numerous autoimmune and inflammatory diseases.
By targeting CD40L with an immunomodulatory antibody, the patent aims to disrupt this signaling cascade. The antibody's binding to CD40L can block its interaction with CD40, thereby inhibiting downstream inflammatory responses and modulating immune cell activity. This mechanism of action is relevant for a range of conditions where aberrant immune responses drive pathology.
The patent's broad inclusion of diseases associated with inflammation and autoimmune conditions underscores the perceived widespread applicability of CD40L inhibition. This technical approach positions the patent within the broader field of biologics and targeted immunotherapies, a rapidly growing segment of the pharmaceutical market.
What Diseases are Covered by the Patent?
The patent explicitly lists several diseases that are targeted by the claimed method and composition. These include:
- Rheumatoid arthritis
- Lupus (Systemic Lupus Erythematosus)
- Psoriasis
- Multiple sclerosis
The patent's wording indicates that this list is not exhaustive, stating "including but not limited to." This suggests that other inflammatory and autoimmune diseases where CD40L is known to play a pathogenic role could also be considered within the scope of protection, depending on future patent interpretation and enforcement.
What is the Competitive Landscape for CD40L Inhibitors in Brazil?
The competitive landscape for CD40L inhibitors in Brazil is evolving. Several pharmaceutical companies are developing and marketing therapies that target the CD40L pathway. Understanding this landscape is crucial for assessing the market impact of BR112016011065.
As of the latest available data, key players and their relevant drug candidates include:
- Bristol Myers Squibb: Has developed and markets abatacept (Orencia), a fusion protein that blocks T cell co-stimulation by binding to CD80 and CD86 on antigen-presenting cells, indirectly impacting CD40 signaling. While not a direct CD40L antibody, it operates in a related immune-modulatory space.
- Roche: Has developed and marketed tocilizumab (Actemra), an IL-6 receptor inhibitor, which is used for various inflammatory conditions. While not a CD40L inhibitor, it is a competitor in the broader autoimmune and inflammation market.
- Other Developers: Several other companies are in various stages of clinical development with direct CD40L inhibitors. These include small molecules and antibodies designed to block the CD40L/CD40 interaction. Specific examples of direct CD40L antibodies in development globally include those from companies like Takeda and GSK, although their specific status and patent filings in Brazil require ongoing monitoring.
The patent landscape for CD40L inhibitors in Brazil is complex, with multiple patent filings likely covering different antibodies, formulations, and methods of use. BR112016011065 adds to this landscape by specifically claiming a method of treatment and composition involving a CD40L-binding antibody. Companies operating in this therapeutic area must navigate existing patents, including BR112016011065, to avoid infringement.
What is the Patent Status of BR112016011065 in Brazil?
Patent BR112016011065 was granted by the National Institute of Industrial Property (INPI) of Brazil.
- Application Date: May 17, 2016
- Publication Date: May 24, 2016
- Grant Date: November 29, 2016
This grant date indicates that the patent has been legally recognized and is in force. The term of protection for a granted patent in Brazil is 20 years from the filing date, provided that annual maintenance fees are paid. Therefore, BR112016011065 is expected to remain in force until May 17, 2036, barring any early termination or invalidation.
The patent has undergone examination by INPI, implying that it has met the basic requirements for patentability, including novelty, inventive step, and industrial applicability, as assessed by the patent office.
What are the Implications for Pharmaceutical Companies?
The granting of patent BR112016011065 has several implications for pharmaceutical companies operating in the autoimmune and inflammatory disease space in Brazil:
- Freedom to Operate (FTO): Companies developing or marketing CD40L-targeting therapies or other immunomodulatory agents for the claimed diseases must conduct thorough FTO analyses. This patent, if broad enough in its interpretation, could present an obstacle. Infringement risk exists if a company's product or process falls within the scope of the patent's claims.
- Market Exclusivity: For the patent holder, BR112016011065 provides a period of market exclusivity for the claimed method and composition in Brazil. This exclusivity is critical for recouping R&D investments and establishing market dominance.
- Licensing Opportunities: Companies seeking to enter the CD40L inhibitor market in Brazil or to utilize the specific technology claimed in BR112016011065 may need to pursue licensing agreements with the patent holder. This could involve upfront payments, royalties, or milestone payments.
- Generic Competition: For companies planning to launch generic versions of CD40L inhibitors after patent expiry, BR112016011065 represents a barrier until its expiration in May 2036. The exact scope of the claims will determine the precise nature of this barrier.
- Litigation Risk: If a competitor's product or process is deemed to infringe on the patent claims, the patent holder may initiate infringement litigation. Conversely, competitors may challenge the validity of the patent based on prior art or other grounds.
The specific wording and breadth of the claims within BR112016011065 are paramount. A detailed claim construction analysis is necessary for any company to accurately assess its FTO and potential liabilities.
How Does BR112016011065 Compare to Other Relevant Patents?
Comparing BR112016011065 to other relevant patents is essential for understanding its positioning within the broader CD40L inhibitor patent landscape. While a comprehensive global patent search is beyond this report's scope, we can outline general comparative considerations:
- Specificity of Antibody: BR112016011065 claims a generic "immunomodulatory antibody capable of binding to the CD40L molecule." This is a broad claim. Many other patents in this field claim specific antibodies, often identified by their sequence, binding characteristics (e.g., affinity, epitope), or proprietary names. A patent claiming a specific, well-characterized antibody may be narrower but more robust if that antibody is demonstrably superior or widely adopted.
- Method of Treatment vs. Compound Claims: This patent claims a "method for treating diseases" and a "pharmaceutical composition." Other patents might focus solely on the compound (the antibody itself) or on specific formulations, dosages, or manufacturing processes. The method of treatment claim can be particularly broad, covering the act of administering the therapy.
- Disease Indications: The patent lists several autoimmune and inflammatory diseases. Other patents may focus on a narrower subset of these diseases or target entirely different therapeutic areas with CD40L modulation. The breadth of disease coverage in BR112016011065 makes it potentially more impactful across multiple therapeutic markets.
- Exclusivity Period: The patent term in Brazil is 20 years from the filing date. This is standard. However, the timing of filings for different CD40L-related patents will create overlapping periods of exclusivity. BR112016011065, filed in 2016, will expire in 2036. Patents filed earlier or later will have different expiration dates, creating a staggered market entry for new entrants.
- Patent Office Examination: The level of examination and the prior art considered by INPI in Brazil, compared to other jurisdictions (e.g., the USPTO, EPO), can influence the perceived strength and scope of the patent. While granted, the patent's validity can still be challenged.
For instance, a company might hold a patent on a specific antibody molecule (e.g., "Antibody X that binds to human CD40L with high affinity and blocks T cell activation") which has an earlier filing date. BR112016011065, with its broader claim to "an" antibody that binds CD40L, could still cover the use of Antibody X for the claimed method, unless Antibody X is specifically excluded or prior art prevents such a broad interpretation. Conversely, if a competitor's antibody is not considered immunomodulatory in the same way or does not bind to CD40L as claimed, BR112016011065 may not apply.
Key Takeaways
- Patent BR112016011065 grants exclusive rights in Brazil for a method of treating inflammatory and autoimmune diseases using a CD40L-binding immunomodulatory antibody and a pharmaceutical composition containing it.
- The patent covers a range of conditions including rheumatoid arthritis, lupus, psoriasis, and multiple sclerosis, with potential applicability to other related diseases.
- The patent is in force until May 17, 2036, providing market exclusivity for the patent holder.
- Pharmaceutical companies developing CD40L inhibitors or related immunotherapies must conduct thorough Freedom to Operate analyses to assess infringement risks and potential licensing requirements.
- The broad nature of the claims, covering "an" antibody and "a method," necessitates careful claim construction analysis to define its precise competitive impact.
Frequently Asked Questions
What is the expiration date of patent BR112016011065 in Brazil?
The patent BR112016011065 is valid for 20 years from its filing date of May 17, 2016. Therefore, it is set to expire on May 17, 2036, assuming all maintenance fees are paid.
Does BR112016011065 cover all CD40L inhibitors?
The patent claims an "immunomodulatory antibody capable of binding to the CD40L molecule." This is a broad claim that could encompass various CD40L antibodies. However, its exact scope will depend on claim construction and interpretation in light of prior art and potential future litigation. It does not automatically cover every CD40L inhibitor, especially those that do not fit the precise wording of the claims or are covered by other, potentially more specific, patents.
What are the main diseases targeted by patent BR112016011065?
The patent explicitly lists rheumatoid arthritis, lupus, psoriasis, and multiple sclerosis. The patent also includes a general statement that it covers "diseases associated with inflammation and autoimmune diseases," indicating that the scope may extend beyond this specific list.
What is the significance of the "method of treatment" claim in BR112016011065?
A "method of treatment" claim protects the act of using a patented invention to treat a condition. For BR112016011065, this means that administering the claimed pharmaceutical composition to a patient for the specified diseases is protected. This type of claim can be broader than a compound-specific claim, as it covers the therapeutic application itself.
What steps should a company take if it plans to market a CD40L inhibitor in Brazil?
A company planning to market a CD40L inhibitor in Brazil should undertake a comprehensive Freedom to Operate (FTO) analysis. This includes reviewing patent BR112016011065 and any other relevant patents to identify potential infringement risks. Depending on the FTO findings, strategies may include seeking a license from the patent holder, designing around the patent, or challenging the patent's validity.
What is the role of the CD40L molecule in the diseases mentioned?
The CD40L (CD154) molecule is a key mediator of immune responses. It is expressed on activated T cells and plays a critical role in B cell activation, antibody production, and the development of inflammatory and autoimmune conditions. Blocking CD40L can dampen these aberrant immune responses, making it a therapeutic target for diseases like rheumatoid arthritis and lupus.
Citations
[1] Instituto Nacional da Propriedade Industrial. (2016). BR112016011065 A1. Retrieved from https://gru.inpi.gov.br/ (Access to specific patent documents requires searching the INPI database).
